Interleukin-10 Is a Promising Marker for Immune-Related Adverse Events in Patients With Non-Small Cell Lung Cancer Receiving Immunotherapy

BACKGROUND: Immune checkpoint inhibitors (ICIs) brought about a major paradigm shift in non-small cell lung cancer (NSCLC) treatment. However, the use of ICIs is related to an unforeseeable pattern of immune-related adverse events (irAEs). Hence, more precise biomarkers are needed to predict the inc...

Descripción completa

Detalles Bibliográficos
Autores principales: Wang, Haowei, Zhou, Fei, Zhao, Chao, Cheng, Lei, Zhou, Caicun, Qiao, Meng, Li, Xuefei, Chen, Xiaoxia
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2022
Materias:
Immunology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8863608/
https://www.ncbi.nlm.nih.gov/pubmed/35222434
http://dx.doi.org/10.3389/fimmu.2022.840313

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8863608/
https://www.ncbi.nlm.nih.gov/pubmed/35222434
http://dx.doi.org/10.3389/fimmu.2022.840313

Ejemplares similares